Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers.
Harrington KJ, Karapanagiotou EM, Roulstone V, Twigger KR, White CL, Vidal L, Beirne D, Prestwich R, Newbold K, Ahmed M, Thway K, Nutting CM, Coffey M, Harris D, Vile RG, Pandha HS, Debono JS, Melcher AA. Harrington KJ, et al. Among authors: twigger kr. Clin Cancer Res. 2010 Jun 1;16(11):3067-77. doi: 10.1158/1078-0432.CCR-10-0054. Epub 2010 May 18. Clin Cancer Res. 2010. PMID: 20484020 Free PMC article. Clinical Trial.
REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.
Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, Vile R, Melcher A, Coffey MC, Mettinger KL, Nuovo G, Cohn DE, Phelps M, Harrington KJ, Pandha HS. Comins C, et al. Among authors: twigger k. Clin Cancer Res. 2010 Nov 15;16(22):5564-72. doi: 10.1158/1078-0432.CCR-10-1233. Epub 2010 Oct 6. Clin Cancer Res. 2010. PMID: 20926400 Free PMC article. Clinical Trial.
Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.
Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, Newbold K, Gore ME, Larkin J, Syrigos KN, Coffey M, Thompson B, Mettinger K, Vile RG, Pandha HS, Hall GD, Melcher AA, Chester J, Harrington KJ. Karapanagiotou EM, et al. Among authors: twigger k. Clin Cancer Res. 2012 Apr 1;18(7):2080-9. doi: 10.1158/1078-0432.CCR-11-2181. Epub 2012 Feb 7. Clin Cancer Res. 2012. PMID: 22316603 Free PMC article. Clinical Trial.
Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.
White CL, Twigger KR, Vidal L, De Bono JS, Coffey M, Heinemann L, Morgan R, Merrick A, Errington F, Vile RG, Melcher AA, Pandha HS, Harrington KJ. White CL, et al. Among authors: twigger kr. Gene Ther. 2008 Jun;15(12):911-20. doi: 10.1038/gt.2008.21. Epub 2008 Mar 6. Gene Ther. 2008. PMID: 18323793 Clinical Trial.
Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy.
Roulstone V, Twigger K, Zaidi S, Pencavel T, Kyula JN, White C, McLaughlin M, Seth R, Karapanagiotou EM, Mansfield D, Coffey M, Nuovo G, Vile RG, Pandha HS, Melcher AA, Harrington KJ. Roulstone V, et al. Among authors: twigger k. Gene Ther. 2013 May;20(5):521-8. doi: 10.1038/gt.2012.68. Epub 2012 Aug 16. Gene Ther. 2013. PMID: 22895509 Free PMC article.
16 results